UCB gets FDA approval for Bimzelx for hidradenitis suppurativa
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 20 2024
0mins
Should l Buy ?
FDA Approval for Bimzelx: UCB has received FDA approval for its drug Bimzelx, making it the first IL-17A and IL-17F inhibitor approved for moderate-to-severe hidradenitis suppurativa (HS).
Additional Approvals: Bimzelx is also approved for other conditions including plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
